During the last session, Beam Therapeutics Inc (NASDAQ:BEAM)’s traded shares were 0.88 million, with the beta value of the company hitting 1.90. At the end of the trading day, the stock’s price was $27.93, reflecting an intraday loss of -0.46% or -$0.13. The 52-week high for the BEAM share is $49.50, that puts it down -77.23 from that peak though still a striking 25.38% gain since the share price plummeted to a 52-week low of $20.84. The company’s market capitalization is $2.31B, and the average intraday trading volume over the past 10 days was 1.09 million shares, and the average trade volume was 1.06 million shares over the past three months.
Beam Therapeutics Inc (BEAM) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.89. BEAM has a Sell rating from 0 analyst(s) out of 6 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Beam Therapeutics Inc (NASDAQ:BEAM) trade information
Beam Therapeutics Inc (BEAM) registered a -0.46% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -0.46% in intraday trading to $27.93, hitting a weekly high. The stock’s 5-day price performance is 4.57%, and it has moved by 1.56% in 30 days. Based on these gigs, the overall price performance for the year is -1.24%. The short interest in Beam Therapeutics Inc (NASDAQ:BEAM) is 10.68 million shares and it means that shorts have 8.86 day(s) to cover.
The consensus price target of analysts on Wall Street is $57, which implies an increase of 51.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $39 and $69 respectively. As a result, BEAM is trading at a discount of -147.05% off the target high and -39.63% off the low.
Beam Therapeutics Inc (BEAM) estimates and forecasts
Statistics show that Beam Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Beam Therapeutics Inc (BEAM) shares have gone up 12.30% during the last six months, with a year-to-date growth rate less than the industry average at -170.93% against 17.10.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 5.58%. While earnings are projected to return -174.65% in 2024, the next five years will return -3.70% per annum.
BEAM Dividends
Beam Therapeutics Inc is due to release its next quarterly earnings in January. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Beam Therapeutics Inc (NASDAQ:BEAM)’s Major holders
Beam Therapeutics Inc insiders own 1.41% of total outstanding shares while institutional holders control 93.14%, with the float percentage being 94.48%. FARALLON CAPITAL MANAGEMENT LLC is the largest shareholder of the company, while 330.0 institutions own stock in it. As of 2024-06-30, the company held over 7.91 million shares (or 9.6857% of all shares), a total value of $185.4 million in shares.
The next largest institutional holding, with 7.9 million shares, is of VANGUARD GROUP INC’s that is approximately 9.6701% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $185.11 million.
